Merck Sharp + Dohme Corp.

Medshine Discovery Inc.

Shijiazhuang Sagacity New Drug Development Company, Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Chinese Pla General Hospital

Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory

Wuxi Biocity Biopharmaceuticals Co., Ltd.

Nicoya Therapeutics (shanghai) Co., Ltd

Wuxi Biocity Biopharmaceutics Co., Ltd.

Shenzhen Optimum Biological Technology Co., Ltd

Wuxi Life Fountain Biotech Co., Ltd

Yunfu Luo

Scott D Kuduk

Nigel J Liverton

Shuhui Chen

Maoyi Lei

Tingting Yu

Na Meng

Douglas C Beshore

Jian Li

Craig Alan Coburn

Milana M Maletic

Zhiqi Qi

Yu Xu

Junmiao Li

Richard Soll

Chundao Yang

Guoli Zhang

Yongxin Han

Guoping Hu

Chun Sing Li

Kenneth L Arrington

Mehul F Patel

Chunsing Li

Yuyong Ba

Jinghong Dong

Xin Li

Lei Zhang

Peng Zhang

Yong Wang

Christopher S Burgey

Chen Bo Li

Feng Gao

Jason W Skudlarek

Bin Chen

Jiayi Xu

Ling Liu

Chen Li

Shaolong Li

Xuefeng Sun

Ping Dong

Xiawei Wei

Kunlun He

Chunlei Liu

Ting Yao

Zhiyu Lei

Shujie Yuan

Zeyu Zhang

Jianfeng Pan

Ran Wei

Sheng Su

Yuanyuan Sun

Jing Gao

Yiwei Wang

Xiaojian Gao

Jiaji Liu

Lanbao Sun

Zhaoying Xu

Wenli Li

Robert Gilfillan

Yaozong Li

Xinchun Yang

Jinlong Zhao

Daoxu Zhang

Mingda Sun

Tao Wei

Huanan Zhao

Mehul Patel

Christopher Burgey

Miao Yang

Wanjing Li

Zhong Xu

Hui Hui

Yanhe Chen

Xiongfeng Ji

Pengyue Bao

Wenjun Yao

Weizhi Ge

Disclosed are a series of compounds having pyridine structures or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of drugs for the treatment of related diseases. Specifically, disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Pyridine derivative and application thereof

A crystal form of compound 1, a solvate thereof, a crystal form of the solvate thereof, and a preparation method therefor. Further comprised is an application of the crystal forms in the preparation of a medicament for treating diseases related to TNFα.

Crystal form of benzimidazole-2-one compound, solvate thereof, crystal form of solvate thereof, and preparation method thereof

Disclosed are a Crystal Form (I) of a pyrimidine sulfonamide compound and a preparation method therefor. The present disclosure relates to an application thereof in the preparation of a medicament for treating diseases related to ETreceptor antagonists.

Crystal form of pyrimidine sulfonamide compound and preparation method therefor

Provided is a fused tri-cyclic compound as PDE3/PDE4 dual inhibitor, and a use thereof in the preparation of drugs for PDE3/PDE4 associated diseases, particularly in medicinal functions such as chronic obstructive pulmonary disease (COPD). Provided are specifically a compound of formula (I) and a pharmaceutically acceptable salt thereof.

Fused tri-cyclic compound as PDE3/PDE4 dual inhibitor

A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.

Bicyclic compound that acts as CRBN protein regulator

The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.

Medical application of pyrimidine sulfonamides derivatives

Disclosed are a crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and a preparation process therefor, and use of the crystal form in the manufacture of a medicament for treating a disease associated with PDE4 receptor. 

Crystal form of 1H-imidazo[4,5-b]pyridine-2(3H)-one compound and preparation process therefor

Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETreceptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof. 

Pyrimidine sulfamide derivative and preparation method and medical application thereof

Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof. 

Tricyclic furan-substituted piperidinedione compound

Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. 

Biphenyl compound as CCR2/CCR5 receptor antagonist

A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof. 

CXCR2 antagonist

The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

Piperidine or piperazine linked imidazole and triazole derivatives and methods of use

Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof. 

PDE4 inhibitor

Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof. 

Cyclic compound acting as PDE4 inhibitor

The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Fused heteroaryl derivatives as orexin receptor antagonists

Growing community of inventors

Shanghai, China

Yunfu Luo